Verona Pharma Plc Stock Current Asset
| VRNA Stock | USD 39.63 0.27 0.68% |
Verona Pharma PLC fundamentals help investors to digest information that contributes to Verona Pharma's financial success or failures. It also enables traders to predict the movement of Verona Stock. The fundamental analysis module provides a way to measure Verona Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Verona Pharma stock.
The current year's Non Current Assets Total is expected to grow to about 19.3 M. The current year's Other Current Assets is expected to grow to about 7.3 M. Verona | Current Asset |
Verona Pharma PLC Company Current Asset Analysis
Verona Pharma's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Verona Current Asset Historical Pattern
Today, most investors in Verona Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Verona Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Verona Pharma current asset as a starting point in their analysis.
Verona Pharma Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Verona Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Verona Pharma PLC has a Current Asset of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Verona Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Verona Pharma from analyzing Verona Pharma's financial statements. These drivers represent accounts that assess Verona Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Verona Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 993.9M | 57.1M | 397.5M | 1.7B | 1.6B | 3.0B | |
| Enterprise Value | 968.8M | 28.3M | 254.9M | 1.5B | 1.4B | 1.3B |
Verona Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Verona Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Verona Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Verona Fundamentals
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (6.94) % | ||||
| Current Valuation | 3.05 B | ||||
| Shares Outstanding | 81.83 M | ||||
| Shares Owned By Insiders | 4.13 % | ||||
| Shares Owned By Institutions | 89.41 % | ||||
| Number Of Shares Shorted | 5.98 M | ||||
| Price To Earning | (9.15) X | ||||
| Price To Book | 25.02 X | ||||
| Price To Sales | 580.56 X | ||||
| Revenue | 458 K | ||||
| Gross Profit | 112 K | ||||
| EBITDA | (52.47 M) | ||||
| Net Income | (54.58 M) | ||||
| Cash And Equivalents | 111.51 M | ||||
| Cash Per Share | 1.83 X | ||||
| Total Debt | 51.33 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 3.57 X | ||||
| Book Value Per Share | 1.59 X | ||||
| Cash Flow From Operations | (50.22 M) | ||||
| Short Ratio | 5.78 X | ||||
| Earnings Per Share | (2.00) X | ||||
| Target Price | 46.57 | ||||
| Number Of Employees | 79 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 3.27 B | ||||
| Total Asset | 308.12 M | ||||
| Retained Earnings | (388.43 M) | ||||
| Working Capital | 281.02 M | ||||
| Net Asset | 308.12 M |
About Verona Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Verona Pharma PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Verona Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Verona Pharma PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Verona Pharma PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verona Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verona Pharma Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verona Pharma Plc Stock:Check out Verona Pharma Piotroski F Score and Verona Pharma Altman Z Score analysis. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.00) | Revenue Per Share 0.07 | Return On Assets (0.28) | Return On Equity (0.78) |
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.